香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） （股份代號： 882） 根據上市規則第 13.18 條作出之 公 告 本公告乃根據上市規則第 13.18 條之規定，就本公司與貸款人於二零二 五年九月十七日簽訂之該融資協議而作出 。該融資協議內載有本公司控 股股東須履行特定責任之條款。 本公告乃根據香港聯合交易所 有限公司證券上市規則（「上市規則 」）第 13.18 條之規定而作出。 天津發展控股有限公司（「 本公司 」）董事會（「 董事會 」）謹此宣佈， 本公司作為借款人與一組銀團作為貸款人（「貸款人 」）已於二零二五年 九月十七日就一項上限為港幣 2,000,000,000 元的有期貸款簽訂融資協議 （ 「該融資協議 」），自提款之日起為期三十六個月。 根據該融資協議，若出現（其 中包括）以下情況，即屬違約事件： 當出現違約事件之時及之後持續發生的任何時間，代表貸款人之代理或會 或將會（倘貸款人之大多數就此要求）向本公 ...

该基金将主要投资于未上市公司的股权(包括其可转股债券)及或上市公司以非公开形式所发行或交易的 股票，而该等公司须为在中国的大健康及生物技术领域，包括创新药、医疗器械、体外诊断器械 (IVD)、医疗服务、「CXO」及相关医药外包服务、制药相关设备或耗材、生命科学仪器及工具、医疗 科技(医疗大数据、AI生命科学、互联网医疗等)、合成生物学、生物农业、生物质能、脑科学、医疗消 费品、养老、中医药、细胞、基因治疗及投资决策委员会认可该等领域的其他优质项目。 格隆汇9月10日丨天津发展(00882.HK)宣布，于2025年9月10日，力生制药(公司间接非全资附属公司)与 建信股权、泰达私募、共青城建兴、泰达国际、国资母基金及战新基金订立合伙协议，据此，该基金将 以人民币5亿元(相当于于港币5.47亿元)的认缴出资总额设立，其中，力生制药(作为有限合伙人)已向该 基金认缴出资人民币1.74亿元(相当于约港币1.9亿元)，占该基金认缴出资总额的34.75%，惟须受合伙协 议的条款及条件所规限。 ...

Core Viewpoint - Tianjin Development (00882) announced a partnership agreement involving its indirect non-wholly owned subsidiary, Lifescience Pharmaceutical, to establish a fund with a total subscription amount of RMB 500 million (approximately HKD 547 million) [1] Group 1: Fund Structure and Investment Focus - The fund will primarily invest in equity of unlisted companies and/or stocks issued or traded in a non-public manner by listed companies, focusing on the health and biotechnology sectors in China, including innovative drugs, medical devices, and related services [1] - Lifescience Pharmaceutical has committed RMB 174 million (approximately HKD 190 million), representing 34.75% of the total subscription amount for the fund [1] Group 2: Risk Management and Investment Strategy - By participating in the fund, Lifescience Pharmaceutical's cost risk is limited to its subscribed amount, avoiding additional expenses and debts compared to direct investments [2] - The fund's investment decisions require approval from the investment decision committee, ensuring that decisions are made with the consent of both Jianxin Equity and Teda Private Equity [2] Group 3: Strategic Benefits and Long-term Outlook - Participation in the fund will enhance the group's understanding of the latest developments in the pharmaceutical industry, diversify investment risks, and identify potential strategic partners for future opportunities [3] - The investment is expected to provide opportunities for mergers and acquisitions aligned with the company's strategic goals, improve capital allocation efficiency, and enhance the company's sustainable operational capabilities [3]

須予披露及關連交易 設立基金 合夥協議 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） （股份代號： 882） 緒言 茲提述本公司日期為二零二五年八月二十二日之公告，內容有關可能設立該基 金。本公司獲力生製藥通知，有關批准訂立合夥協議及其項下擬進行之交易 （包括建議設立該基金）的股東決議案已於其在二零二五年九月八日舉行的股 東大會上獲正式通過。 於二零二五年九月十日，力生製藥（本公司間接非全資附屬公司）與建信股 權、泰達私募、共青城建興、泰達國際、國資母基金及戰新基金訂立合夥協 議，據此，該基金將以人民幣500,000,000元（相當於約港幣547,045,952元） 的認繳出資總額設立，其中，力生製藥（作為有限合夥人）已向該基金認繳 出資人民幣173,750,000元（相當於約港幣190,098,468元），佔該基金認繳出 資總額的34.75%，惟須受合夥協議的條款及條件所規限。 上市規則涵義 由於根據上市規則第14. ...

Group 1 - The company Tianjin Development (00882) announced a financial agreement with Industrial Bank for a structured deposit [1] - The agreement involves an investment of RMB 70 million, equivalent to approximately HKD 76.5864 million [1] - This marks the 10th financial agreement between the company’s indirect non-wholly owned subsidiary, Lifescience Pharmaceutical (002393), and Industrial Bank [1]

格隆汇9月10日丨天津发展(00882.HK)公布，于2025年9月10日，力生制药(公司间接非全资附属公司)与 兴业银行订立第十份兴业银行理财协议，以本金金额人民币7000万元认购另一项结构性存款。 ...

（於香港註冊成立之有限公司） （股份代號：882） 須予披露交易 認購興業銀行理財產品 第十份興業銀行理財協議 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 茲提述本公司日期二零二五年六月十一日及二零二五年六月十九日之公告， 內容有關前理財協議。 於二零二五年九月十日力生製藥（本公司間接非全資附屬公司）與興業銀行 訂立第十份興業銀行理財協議，以本金金額人民幣 70,000,000 元（相當於約 港幣 76,586,433 元）認購另一項結構性存款。 上市規則涵義 新認購事項（按單獨基準計算）不構成本公司於上市規則第 14 章項下的須 予公佈交易。 由於前認購事項及新認購事項均為本集團向同一銀行購入理財產品並仍然持 有的投資，故根據上市規則第 14.22 條，該等認購事項須作為一系列交易合 併計算。 由於根據上市規則第 14.07 條計算有關新認購事項的其中一項適用百分比率 （與前認購事項合併計算時）超過 5%但低於 25%，新認購事項構成本公司 的 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 天津發展控股有限公司 | | | 呈交日期: | 2025年9月1日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00882 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 1,072,770,125 | | 0 | | 1,072,770,125 | | 增加 / 減少 ...

Performance Summary - SF Holding reported a revenue of 146.858 billion yuan, a year-on-year increase of 9.26%, and a net profit of 5.738 billion yuan, up 19.37% year-on-year [2] - Shanghai Pharmaceuticals achieved a revenue of 141.593 billion yuan, a growth of 1.56%, with a net profit of 4.459 billion yuan, increasing by 51.56% [2] - New China Life Insurance's revenue reached 69.429 billion yuan, a 25.5% increase, and a net profit of 14.799 billion yuan, up 33.5% [2] - Huadian International Power's revenue was 59.953 billion yuan, down 8.98%, while net profit increased by 13.15% to 3.904 billion yuan [2] - China Pacific Insurance reported a revenue of 55.964 billion yuan, a slight increase of 0.2%, and a net profit of 6.764 billion yuan, up 12.2% [2] - CITIC Securities had a revenue of 46.552 billion yuan, a 16.28% increase, and a net profit of 13.719 billion yuan, up 29.79% [2] - Beijing Enterprises Holdings reported a revenue of 44.529 billion yuan, a 5.2% increase, and a net profit of 3.404 billion yuan, up 8.1% [2] - Li Auto's vehicle sales revenue for Q2 2025 was 28.9 billion yuan, down 4.7%, with a net profit of 1.093 billion yuan, a decrease of 0.9% [2] - Huishang Bank reported a revenue of 21.157 billion yuan, a 2.25% increase, and a net profit of 9.109 billion yuan, up 5.55% [2] - SMIC achieved a revenue of 4.456 billion USD, a 22% increase, with a net profit of 320 million USD, up 35.6% [2] - China Galaxy Securities reported a total revenue of 18.798 billion yuan, an 18.92% increase, and a net profit of 6.488 billion yuan, up 47.86% [2] - Zhongjun Group Holdings had a revenue of 18.521 billion yuan, down 25.4%, with a net loss of 3.48 billion yuan, a narrowing of 5.5% [2] - BeiGene reported a revenue of 2.433 billion USD, a 44.7% increase, and a net profit of 95.59 million USD, turning from a loss of 372 million USD [2] - SF Express City reported a revenue of 10.236 billion yuan, up 48.8%, and a net profit of 137 million yuan, up 120.4% [2] - China Shipbuilding Defense reported a revenue of 10.173 billion yuan, a 16.54% increase, and a net profit of 526 million yuan, up 258.46% [2] - Qingdao Port reported a revenue of 9.434 billion yuan, a 4.04% increase, and a net profit of 2.842 billion yuan, up 7.58% [2] - Shanghai Industrial Holdings reported a revenue of 9.476 billion yuan, down 8.6%, and a net profit of 1.042 billion yuan, down 13.2% [2] - Everbright Securities reported a revenue of 7.481 billion yuan, a 17.7% increase, and a net profit of 1.683 billion yuan, up 21% [2] - Baozun reported a revenue of 4.617 billion yuan, a 5.63% increase, with a net loss of 97.04 million yuan, narrowing [2] - Sichuan Chengyu Expressway reported a revenue of 4.08 billion yuan, down 23.3%, and a net profit of 838 million yuan, up 20.1% [2] - Baideli Holdings reported a revenue of approximately 3.813 billion yuan, down 10.9%, and a net profit of 7.1 million yuan, down 79.1% [2] - Tigermed reported a revenue of 3.25 billion yuan, down 3.21%, and a net profit of 383 million yuan, down 22.22% [2] - Zhengli New Energy reported a revenue of 3.172 billion yuan, a 71.9% increase, and a net profit of 220 million yuan, turning from a loss of 130 million yuan [2] - Sensong International reported a revenue of 2.687 billion yuan, down 22.7%, and a net profit of 338 million yuan, down 10.15% [2] - Dasheng Holdings reported a revenue of approximately 2.593 billion yuan, a 27% increase, and a net profit of 65.924 million yuan, up 504.4% [2] - SenseTime reported a revenue of 2.358 billion yuan, a 35.6% increase, with a gross profit of 908 million yuan, up 18.4%, and an adjusted net loss of 1.162 billion yuan, narrowing by 50% [2] - Ruian Real Estate reported a revenue of 2.074 billion yuan, flat year-on-year, with a net profit of 51 million yuan, down 29.2% [2] - Shangri-La Asia reported a revenue of 1.056 billion USD, a 0.7% increase, and a net profit of 57.9 million USD, down 38.7% [2] - Quanfeng Holdings reported a revenue of 912 million USD, an 11.9% increase, and a net profit of 95.217 million USD, up 54.8% [2] - COSCO Shipping Ports reported a revenue of 806 million USD, a 13.6% increase, and a net profit of approximately 182 million USD, up 30.6% [2] - Tianjin Development reported a revenue of 1.719 billion yuan, down 5.59%, and a net profit of 344 million yuan, up 19.57% [2] Company News - Sillodic Pharmaceuticals successfully administered the new radiolabeled drug 3D1015 to patients with PSMA-positive metastatic castration-resistant prostate cancer, demonstrating safety and preliminary efficacy [2] - Shoucheng Holdings signed a strategic cooperation framework agreement with Alter and Alrite to jointly promote breakthroughs in robotics technology, scene implementation, and industrial chain collaboration [2]

Core Viewpoint - Tianjin Development (00882) reported a net profit attributable to shareholders of HKD 344 million for the six months ending June 30, 2025, representing a year-on-year increase of 19.57% despite a revenue decline [1] Financial Performance - Revenue for the period was HKD 1.719 billion, showing a year-on-year decrease of 5.59% [1] - Basic earnings per share were HKD 0.3211 [1] - The company proposed an interim dividend of HKD 0.0518 per share [1]